Primary Endpoint: PFS by BIRC
Ceritinib
(N=189)
Chemotherapy
(N=187)
Events, n (%)
89 (47.1)
113 (60.4)
Median (95% CI),
months
16.6 (12.6, 27.2)
8.1 (5.8, 11.1)
Hazard ratio (95% CI) = 0.55 (0.42, 0.73)
Stratified Log-rank p-value < 0.001
0
20
40
60
0
PFS probability (%)
100
80
10
Time (months)
2
4
6
8
12 14 16 18 20 22 24 26 28 30 32 34
Ceritinib
155 139
189
125 116 105 98
76
59
43
32
23
16
11
1
1
1
0
Chemotherapy
136 114
187
82
71
60
53
35
24
16
11
5
3
1
1
0
0
0
No. at risk
Ceritinib Demonstrated an Estimated 45% Risk Reduction Vs Chemotherapy
